This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Aptera critiques Zaptera’s ‘inevitable disclosure’ theory of misappropriation

By Melissa Ritti ( March 17, 2025, 13:36 GMT | Insight) -- Dismissal of Zaptera USA’s trade secret misappropriation claims is warranted because the “inevitable disclosure” theory they are premised on has been “roundly rejected by California courts,” Aptera Motors Corp. argued Friday. Also targeted in the motion to dismiss are allegations of infringement of two design patents set to expire in the coming weeks, a potentially dispositive detail in view of the defendants’ position that “pre-order reservations” for its solar-powered electric vehicles — estimated by Zaptera to be worth $1.7 billion — cannot count as “sales" under federal patent law.Aptera Motors Corp. is seeking an early exit from California litigation in which it is accused of misappropriating trade secrets and infringing two soon-to-expire design patents plaintiff Zaptera US says it acquired in an asset purchase agreement over one decade ago....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections